20 Sep Mana.bio
Peter Nell, Ph.D., Advisory Board Member
Oct. 10 | 3:30pm | Rentschler ATMP Ballroom
Mana.bio leverages AI/ML to design novel non-viral ex-liver cell-specific RNA delivery solutions. Mana Bio is a seed-stage biotech company leveraging data, machine learning, and high throughput screening to design novel LNPs for extrahepatic delivery of nucleic acid therapeutics and vaccines. Mana was founded by a team of repeat entrepreneurs and highly regarded experts in the field of drug delivery, machine learning, and software development. Mana built predictive AI models and achieved novel IP-protected in vivo results, including lung-specific delivery of mRNA. The company is now open to leveraging this technology platform for collaborations with biotech and pharma companies to optimize formulations for cell-specific delivery of a wide range of payloads, such as mRNA, CRISPR gRNA, siRNA and more.